Showing results (1551-1560 of 6,794) with videos related to

Sort By:
Pageof 680
Clinical Therapeutics|August 8, 2025
Pegylated Liposomal Doxorubicin Confers a High Risk for Pneumocystis Jirovecii Pneumonia in Patients With Diffuse Large B-Cell LymphomaSiqian Wang, Xi Xu, Yongyong Ma, et al.
Clinical Therapeutics|July 30, 2025
Brexpiprazole Oral Soluble Film: A Randomized, Open-Label, Single-Dose, Crossover Bioequivalence Study in Healthy Chinese VolunteersTian Wang, Lei Shang, Yingxia He, et al.
Clinical Therapeutics|May 3, 2025
Prescription of Pharmacologic Venous Thromboembolism Prophylaxis Upon Hospital Discharge After Surgery for Lower Limb Fracture-A 3-Center Study in the North-West of EnglandFatima Kayali, Hritik Nautiyal, Jonathan Topping, et al.
Clinical Therapeutics|October 10, 2025
Characterizing Fenofibrate-Related Renal and Urinary Adverse Events: A Comprehensive Analysis of FDA Adverse Event Reporting System DatabaseLi Wang, Xiangyun Jin, YanChun Li
Clinical Therapeutics|October 2, 2025
Clinical Study of Cardiac Electrophysiology Affected After Percutaneous Transluminal Septal Myocardial Ablation for Obstructive CardiomyopathyTianzhu Li, Jinzhao Li, Jun Zhang, et al.
Clinical Therapeutics|September 14, 2025
Increasing the Time Interval Suppresses Adverse Effects After Concomitant Use of Nafamostat Mesylate and Levocarnitine in Dialysis Patients: Case SeriesLili Jiang, Jiaoyan Chen, Jurong Yang, et al.
Clinical Therapeutics|September 9, 2025
Oral Ursodeoxycholic Acid Is Associated With Decreased Rate of AMDKevin R Zhang, Rohini M Nair, Yineng Chen, et al.
Clinical Therapeutics|February 8, 2026
Pharmacovigilance Assessment of PD-1 Antibody Therapy in Head and Neck Cancer: Risk Factor Analysis Using FAERS DatabaseQian Gao, Linli Xie, Yu Qin, et al.
Clinical Therapeutics|August 1, 2025
Cost-Effectiveness of Perioperative Nivolumab for Stage III Non-Small-Cell Lung Cancer: A Perspective From The United StatesJingyi Sun, Na Zhang, Qiong Chen, et al.
Clinical Therapeutics|June 14, 2025
Safety and Efficacy of Grapefruit Juice Combined With Low-Dose Venetoclax in AML Patients Ineligible for Intensive ChemotherapyDanchen Meng, YuXin Li, Min Ruan, et al.
Pageof 680